Royalty Pharma(US:RPRX)2025-11-05 13:00Financial Performance - Royalty Pharma achieved double-digit growth in Royalty Receipts, up by 11% year-over-year[9], and Portfolio Receipts, also up by 11% year-over-year[9] - The company's Return on Invested Capital (ROIC) was 157% and Return on Invested Equity (ROIE) was 229% for the last twelve months (LTM) ending in Q3 2025[9] - For FY 2025, Portfolio Receipts are expected to be between $3200 million and $3250 million, excluding future investments, representing a growth of approximately 14% to 16%[10] Capital Allocation - Royalty Pharma deployed $1 billion in capital during Q3 2025, bringing the total to $17 billion for the first nine months of the year[9] - The company repurchased 4 million shares for $152 million in Q3 2025, and a total of 35 million shares for $115 billion in the first nine months[9] Portfolio Updates - Royalty Pharma acquired a royalty on Amgen's Imdelltra for up to $950 million, including $885 million upfront, projecting consensus sales of approximately $27 billion by 2035[19, 20] - The company acquired a 1% royalty on Alnylam's Amvuttra for $310 million, with consensus sales projected to reach approximately $84 billion in 2030[23, 24] - A funding agreement was established with Zenas for obexelimab, providing up to $300 million in funding[9, 27]